Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lymphoma, B-Cell Clinical Trials

A listing of Lymphoma, B-Cell medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Phase

BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

This is a multicenter open-label phase 2 study to evaluate efficacy, safety and tolerability of BGB-3111 160 mg twice daily in combination with rituximab in Chinese Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma. The study is composed of ...

Phase

Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma

Patients with relapsed /refractory diffuse large B cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP. The investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment Gemox regiment (gemcitabineoxaliplatin, dexamethasone) with apatinib ...

Phase

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

Primary Objective: To determine if nivolumab administration, as a maintenance strategy in DLBCL patients with high risk of relapse, can convert positive ctDNA to negative ctDNA and/or result in relapse free survival (RFS-ctDNA) of 9 months or longer after positive ctDNA was documented. Secondary Objectives: To evaluate safety of nivolumab ...

Phase N/A

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.

Phase N/A

Ibrutinib and Standard Immuno-Chemotherapy in Younger High-Risk Patients With Diffuse Large B-Cell Lymphoma

Encouraging results have been achieved in younger high-risk patients with newly diagnosed diffuse large B-cell lymphoma treated with R-CHOEP. However, more than one fourth of patients still relapse or show primary progressive disease. The outcome of such patients is poor, in particular if first-line therapy contained rituximab. In order to ...

Phase

Gazyva Infusion Reaction Investigation

MRD (Minimal residual disease) evaluation was chosen as a primary measure outcome as it is considered as prognostic marker for long-term progression freee survival (PFS) and as a potential therapeutic goal in chronic lymphocytic leukemia/ CLL (M. Kwok et al., Blood, 2016). Minimal residual disease (MRD-negative) is assessed in the ...

Phase N/A

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

A study to assess the real-life management and use of healthcare resources during the initiation of venetoclax in participants with chronic lymphocytic leukemia (CLL) with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who ...

Phase N/A